Kimberly-Clark just announced a $48.7 billion cash-and-stock deal to acquire Kenvue — the company behind Tylenol, Band-Aid, and Neutrogena. This merger would create one of the biggest consumer health companies in the U.S., bringing Huggies, Kleenex, and Tylenol all under one roof. Kenvue stock surged nearly 21% in premarket trading to $17.38 after the news, while Kimberly-Clark shares dropped about 14%. The combined company is expected to generate roughly $32 billion in annual revenue and $7 billion in EBITDA once the deal closes in 2026. What do you think — smart long-term move or too much consolidation in the consumer staples space? #Kenvue #KimberlyClark #Tylenol #StockMarket #FinanceNews